{
    "clinical_study": {
        "@rank": "168063", 
        "arm_group": [
            {
                "arm_group_label": "Mifepristone at home 24 hours before miso dosing starts", 
                "arm_group_type": "Experimental", 
                "description": "All women will receive study packet one containing mifepristone to swallow at home on study day 1.  They will be told to return to the hospital for induction  and will be scheduled to return to the hospital 24 hours later.  Upon their return, they will be hospitalized and receive another study packet containing a placebo. Simultaneously, they will receive one dose of 400 mcg buccal misoprostol. Women will remain hospitalized and receive repeated doses of 400 mcg buccal misoprostol every three hours.\nParticipants will receive up to eight doses of misoprostol (e.g. 3200 mcg misoprostol) over 24 hours. Misoprostol dosing will stop when both the fetus and placenta are expelled."
            }, 
            {
                "arm_group_label": "Mifepristone and first dose of misoprostol simultaneously.", 
                "arm_group_type": "Experimental", 
                "description": "Will receive study packet one containing placebo to swallow at home on study day 1.  They will be told to return to the hospital for induction  and will be scheduled to return to the hospital 24 hours later.  Upon their return, they will be hospitalized and receive another study packet containing mifepristone. Simultaneously they will receive one dose of 400 mcg buccal misoprostol.  Women will remain hospitalized and receive repeated doses of 400 mcg buccal misoprostol every three hours.\nParticipants will receive up to eight doses of misoprostol (e.g. 3200 mcg misoprostol) over 24 hours. Misoprostol dosing will stop when both the fetus and placenta are expelled. The procedure will be considered complete once both the fetus and placenta are expelled."
            }
        ], 
        "brief_summary": {
            "textblock": "A double-blind randomized controlled trial to compare a shorter interval between the\n      administration of mifepristone and misoprostol (simultaneous administration compared to\n      24hours from administration of mifepristone to receipt of the first dose of misoprostol) for\n      termination of pregnancy up to 13-22 weeks of gestation. The investigators hypothesize that\n      a shortened interval may achieve comparable efficacy in terminating pregnancy, whilst\n      reducing the duration of the procedure and in turn, the duration of hospitalization."
        }, 
        "brief_title": "Medical Abortion With Mifepristone + Misoprostol (13 - 22 Weeks)", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": "Complete Uterine Evacuation After Use of Study Drugs", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Closed cervical os and no vaginal bleeding\n\n          -  Live fetus at time of presentation for service\n\n          -  No contraindications to medical abortion and study procedures, according to provider\n\n          -  Able to consent to participate in the study, either by reading consent document or by\n             having consent document read to her and sign informed consent\n\n          -  Willing to follow study procedures\n\n        Exclusion Criteria:\n\n          -  Known previous transmural uterine incision\n\n          -  > 5 parity\n\n          -  Signs and symptoms of infection\n\n          -  Any contraindications to vaginal delivery, including placenta previa\n\n          -  Presentation in active labor (defined as moderate to severe contractions every 10\n             minutes or less)"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "504", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01768299", 
            "org_study_id": "1008"
        }, 
        "intervention": [
            {
                "arm_group_label": "Mifepristone at home 24 hours before miso dosing starts", 
                "description": "200 mg oral Mifepristone 24 hours before 400 mcg buccal misoprostol", 
                "intervention_name": "Mifepristone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Mifepristone and first dose of misoprostol simultaneously.", 
                "description": "200 mg oral Mifepristone simultaneously 400 mcg buccal misoprostol", 
                "intervention_name": "Misoprostol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Mifepristone", 
                "Misoprostol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "abortion", 
            "medical abortion", 
            "mifepristone", 
            "misoprostol"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Ho Chi Minh City", 
                        "country": "Vietnam", 
                        "state": "Binh Duong Province"
                    }, 
                    "name": "Binh duong Obstetrics and Newborn Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hanoi", 
                        "country": "Vietnam"
                    }, 
                    "name": "National Ob-Gyn Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ho Chi Minh City", 
                        "country": "Vietnam"
                    }, 
                    "name": "Hung Vuong Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Vietnam"
        }, 
        "number_of_arms": "2", 
        "official_title": "Medical Abortion With Mifepristone + Misoprostol (13 - 22 Weeks): A Double-blind Randomized-controlled Trial", 
        "overall_official": [
            {
                "affiliation": "Gynuity Health Projects", 
                "last_name": "Jennifer Blum, MPH", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Gynuity Health Projects", 
                "last_name": "Beverly Winikoff, MD, MPH", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Gynuity Health Projects", 
                "last_name": "Dina Abbas, MPH", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hung Vuong Hospital", 
                "last_name": "Nguyen thi Ngoc, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Vietnam: Scientific Committee, Hung Vuong Hospital", 
                "Additional IRB: National Hospital OB-GYN, Hanoi, Vietnam"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Defined as complete evacuation of fetus and placenta using study drug without recourse to any additional intervention.", 
            "measure": "Proportion of women who have had a complete uterine evacuation within 24 hours using study drug without recourse to any additional intervention.", 
            "safety_issue": "No", 
            "time_frame": "Within 1 week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01768299"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Defined as time elapsed between administration of the first misoprostol dose until expulsion of the fetus and placenta.", 
                "measure": "Induction to abortion interval", 
                "safety_issue": "No", 
                "time_frame": "Within 1 week"
            }, 
            {
                "measure": "Women's acceptability of the assigned method.", 
                "safety_issue": "No", 
                "time_frame": "Within 1 week"
            }, 
            {
                "description": "Defined as fetal expulsion with study drug alone.", 
                "measure": "Rate of fetal expulsion", 
                "safety_issue": "No", 
                "time_frame": "Within 1 week"
            }, 
            {
                "description": "For example: Uterine massage, Manual removal, Sponge forceps, D&C or D&E, Repeat medical abortion drugs", 
                "measure": "Provision of additional interventions", 
                "safety_issue": "No", 
                "time_frame": "Within 1 week"
            }, 
            {
                "description": "Defined as length of time from initiation of mifepristone to complete abortion achieved.", 
                "measure": "Time interval from the mifepristone dose to abortion", 
                "safety_issue": "No", 
                "time_frame": "Within 1 week"
            }, 
            {
                "measure": "Total dose of misoprostol administered", 
                "safety_issue": "No", 
                "time_frame": "Within 1 week"
            }
        ], 
        "source": "Gynuity Health Projects", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gynuity Health Projects", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}